FLOMAX
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
FLOMAX by Sanofi is (bph) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. Approved for the signs, symptoms of benign prostatic hyperplasia (bph) [see ], hypertension. First approved in 1997.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOMAX (tamsulosin) is an oral alpha-1A adrenergic receptor antagonist approved in 1997 for benign prostatic hyperplasia (BPH). It works by blocking alpha-1A receptors in the prostate and bladder neck, relaxing smooth muscle and improving urine flow. The drug targets the dynamic component of BPH-related bladder outlet obstruction through sympathetic nervous system blockade.
$2MPart D
LOE ApproachingDeclining
Declining revenue trajectory signals team consolidation; expect shift from growth-focused roles to lifecycle management and generic transition planning.
Mechanism of Action
(BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH…
Indications (2)
Worked on FLOMAX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.